Vita Life Sciences Limited (ASX: VLS) - Share Price
Current share price for VLS : $2.760 0.02 (0.73%)+
Vita Life Sciences Limited (VLS) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a Company that is engaged in formulating, packaging, sales and distribution of vitamins and supplements.
VLS General Information +
| ASX Code | VLS |
| Website | http://www.vitalifesciences.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 149 |
| VLS Share Price | $2.760 |
| Day High | $2.800 |
| Day Low | $2.760 |
| Last Close | $2.740 |
| VLS Share Price Movement | $0.02 ( 0.73% ) |
Prices as at 16:40, 2 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Vita Life Sciences Limited (VLS) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Result | 5¢ | 60% | 18 Sep 2026 | 2 Oct 2026 | - | - | - |
| HFResult | 9.5¢ | 47.37% | 27 Mar 2026 | 10 Apr 2026 | - | - | - |
| Result | 4.5¢ | 100% | 19 Sep 2025 | 3 Oct 2025 | - | - | - |
See all dividends from Vita Life Sciences Limited (VLS) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Vita Life Sciences Limited (VLS) price-sensitive announcements
VLS - Half Yearly Report and Accounts
The half-year report for Vita Life Sciences Limited, ending June 30, 2026, indicates reven
Vita Life Sciences Limited (VLS)
17 Aug 2026 | 5:39 PM
17 Aug 2026 | 5:39 PM
VLS - Guidance
Vita Life Sciences Limited has announced its guidance for the half year ending 30 June 202
Vita Life Sciences Limited (VLS)
12 Jun 2026 | 10:40 AM
12 Jun 2026 | 10:40 AM
VLS - Results of Meeting
The document reports on the results of Vita Life Sciences Limited's 2026 Annual General Me
Vita Life Sciences Limited (VLS)
28 May 2026 | 3:11 PM
28 May 2026 | 3:11 PM
VLS - Preliminary Final Report
Vita Life Sciences Limited reported a robust financial performance for the year ending Dec
Vita Life Sciences Limited (VLS)
16 Feb 2026 | 3:34 PM
16 Feb 2026 | 3:34 PM
Vita Life Sciences Limited (VLS) Recent ASX Announcements
VLS Financial Summary
| Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | $10.43 | $18.40 | 16.20% | 11.70 | 14.00 | 6.50% | 64.0% |
| 2024A | $8.78 | $15.80 | -4.90% | 13.70 | 10.00 | 4.60% | 100.0% |
| 2023A | $9.08 | $16.60 | 26.50% | 9.50 | 9.00 | 5.70% | 100.0% |
VLS Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $783M | 0.4454 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,553M | -0.7857 | 0.2462 | 0.9655 | 86.5492 | 69.4483 | 35.3333 | 0.00% | 1.64% | 1.94% |
| Vita Life Sciences Limited (VLS) | $148M | 0.1621 | 0.0000 | 0.0000 | 14.9319 | 0.0000 | 0.0000 | 5.11% | 0.00% | 0.00% |
VLS Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.20 | 15.00 | 2.72 | 0.00 |
| Market | 0.36 | 13.90 | 1.06 | 0.72 |
| Sector | 0.67 | 31.10 | 2.72 | 1.30 |
VLS Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Andrew O'Keefe | Managing Director | 24 Oct 2016 |
| Mr Jack Teoh | Non-Executive Director | 30 Sep 2022 |
| Mr Peter Osborne | Non-Executive Director | 1 Aug 2023 |
| Mr Henry George Townsing | Non-Executive Director, Non-Executive Chairman | 22 Dec 2011 |
Vita Life Sciences Limited (VLS) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 1 Sep 2026 | TOWNSING, Henry | Buy | Indirect Shares | 30,000 | $2.760 | $82,800.000 |
| 9 Jun 2026 | O'KEEFE, Andrew | Issued | Direct Shares | 600,000 | $2.525 | $1,515,000.000 |
| 5 Jun 2026 | TOWNSING, Henry | Sell | Indirect Shares | 23,184 | $2.431 | $56,367.259 |
See all changes in directors' interest & trades for Vita Life Sciences Limited (VLS) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
VLS Management
| Name | Position |
|---|---|
| Chin Leng Khoo | Chief Financial Officer,Company Secretary |
VLS Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Vita Life Sciences Limited (VLS). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 8,551,439 (15.40%) | Chemical Overseas Limited |
| 8,435,693 (15.20%) | Vicky Teoh |
| 7,371,832 (13.30%) | Barings Acceptance Limited |
| 6,276,040 (11.30%) | Anglo Australian Christtan and Charitable Fund |
| 4,010,000 (7.20%) | Tie Lim Sung |
| 2,870,584 (5.10%) | SG Hiscock & Company Limited |
VLS Calendar of Events
| Date | Event |
|---|---|
| 17 August 2027 | Report (Interim) |
| 16 August 2027 | Report (Interim) |
| 25 March 2027 | Report (Annual) |
| 15 February 2027 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
